PAPZIMEOS Revenue Jumps 37% to $72.9M; Precigen Turns Cash Flow Positive a Quarter Early
PGEN sits 65% above its 52-week low of $3.04 on elevated volume (1.8× avg).
Summary
PAPZIMEOS net revenue climbed 37% quarter-over-quarter to $72.9 million, pushing total Q3 revenue to $74.1 million and net income to $35.8 million, or $0.08 per diluted share. That follows the first profitable quarter in Q2, when net income was $20.1 million on $53.1 million in Papzimeos sales — the ramp is holding, not flattening. Management hit positive operating cash flow ($11.9 million) a full quarter ahead of its own guidance, which removes the financing overhang that has hung over this name. Cash, equivalents and investments stood at $51.0 million on September 30 against $94.3 million of long-term debt, so the balance sheet is still levered but no longer burning. Adoption metrics back the numbers: over 500 patients have started treatment and more than 300 have completed it, with payer coverage across over 315 million US lives. The EMA is reviewing the MAA submitted in November 2025, and the company plans to present new Phase 2 PRGN-2009 data at a forthcoming R&D Day.
At the time of this announcement, PGEN was trading at $5.01 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.8B. The 52-week trading range was $3.04 to $8.98. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.